HOME >> BIOLOGY >> NEWS
Discovery could improve anemia treatment in patients

ext step is to determine whether drugs that inhibit HFE or hepcidin will be useful," says Senior Investigator Dr. Nancy Andrews, a Howard Hughes Medical Institute investigator at Children's Hospital Boston and the Leland Fikes Professor of Pediatrics at Harvard Medical School.

Roy notes that it may not be desirable to inactivate hepcidin completely. The hormone's antimicrobial properties would be lost and allowing too much iron to circulate also can promote infection. "It's going to be a balance," Roy says. "If we manipulate hepcidin activity, we have to be very careful not to encourage infection while we're trying to resolve the anemia. The ideal would be to control infection while allowing enough iron for red blood cell production."

HFE has long been known to control iron absorption. Andrews' lab has previously shown that a lack or a defect in HFE causes an opposite condition -- hereditary hemochromatosis (iron overload). People with this condition absorb too much iron, and as iron levels build up, they can develop liver cancer, heart disease, and other fatal conditions. "Living organisms have evolved intricate mechanisms to regulate iron uptake and distribution so they can exploit iron's useful properties while avoiding toxicity," notes Andrews.

Andrews and Roy are intrigued by the interaction of HFE and hepcidin, because it suggests that HFE has an immunologic function as well as an iron-regulating function. "We don't yet understand the immunity connection," says Andrews, who also holds a doctorate in biology. "Many molecules important in iron metabolism are also involved in immune defense, or are related to molecules involved in immune defense. But we don't yet know why." EMBL Scientists Martina Muckenthaler and Matthias Hentze collaborated closely with the Children's/Harvard team to identify this link.

"Our results clearly link HFE to the development of this type of anemia. More importantly, it seems that you can affect HFE f
'"/>

Contact: Mary-Ellen Shay
mary.shay@childrens.harvard.edu
617-355-6420
Children's Hospital Boston
18-Apr-2004


Page: 1 2 3

Related biology news :

1. Discovery of new shrimp species adds to unique family
2. Discovery of tiny microbes in ancient Greenland glacier may define limits for life on Earth
3. Discovery in parasite movement may offer insights into malaria
4. Scientists find second way to kill cancer cells: Discovery opens possibilities for new therapies
5. GlaxoSmithKline Drug Discovery and Development Research Grant Program 2004
6. Discovery helps explain how cells package DNA
7. Discovery offers clues to origin of life
8. Discovery could lead to better treatment for cryptosporidum infections
9. Discovery of brain disorder gene paves way for genetic test
10. Discovery may be first plant cell surface molecule that halts cell proliferation
11. Discovery may help in war against fire ants

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/2/2020)... ... July 01, 2020 , ... AltruBio Inc. http://www.altrubio.com , ... biologic for the treatment of steroid-refractory acute graft-versus-host disease (SR-aGVHD), at European Hematology ... Martin of the Fred Hutchinson Cancer Research Center, this single-arm, open-label Phase 1 ...
(Date:7/1/2020)... ... July 01, 2020 , ... Cure Glioblastoma, a registered ... common and aggressive adult brain cancer—announced today the appointments of its first Senior ... with supporting the organization’s initiatives and overall vision. , "Senior Fellows are more ...
(Date:6/25/2020)... MANSFIELD, Mass. (PRWEB) , ... June 24, 2020 ... ... provider of cloud-based enterprise software and software-driven clinical data services that accelerate drug ... trials for low-dose selinexor, an XPO1 inhibitor, in hospitalized patients with severe COVID-19. ...
Breaking Biology News(10 mins):
(Date:7/31/2020)... SOMERSET, N.J (PRWEB) , ... July 29, 2020 ... ... editing company, and Catalent, the leading global provider of advanced delivery technologies, development, ... products, today announced that they have entered into a strategic partnership whereby Catalent ...
(Date:7/22/2020)... ... July 22, 2020 , ... Join experts from ... Sr. Manager Regulatory Solutions, in a one hour live webinar on Thursday, ... body in China for drugs and medical devices. Specifically, for medical devices, the NMPA ...
(Date:7/18/2020)... ... July 17, 2020 , ... dicentra , a ... and food industries, is pleased to announce that Charles Galea has joined its ... , Charles is an accomplished and results-driven sales executive with over 10 years ...
(Date:7/10/2020)... ... 2020 , ... Sentien Biotechnologies, Inc., a clinical-stage biotechnology company ... Nissenson, M.D., F.A.C.P., as its Chief Medical Officer. Dr. Nissenson will join ... Dr. Nissenson serves as an Emeritus Professor of Medicine at the David ...
Breaking Biology Technology:
Cached News: